China Clamps Down On Chemical Firm Drug Ingredients
This article was originally published in PharmAsia News
China plans to have in place by the end of this year a new system to control ingredients used in pharmaceuticals. The State FDA says it will focus on ingredients made by chemical firms for the medicine market along with higher production standards. The stricter controls are a response, in part, to complaints of contaminated and other problem goods produced in China for foreign markets. The SFDA and other agencies also plan to keep a closer eye on chemical firms that seek to move into the pharmaceutical market. (Click here for more
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.